{"name":"Akros Pharma Inc.","slug":"akros-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"JTT-861 Capsules","genericName":"JTT-861 Capsules","slug":"jtt-861-capsules","indication":"Other","status":"phase_2"},{"name":"Placebo for comparator","genericName":"Placebo for comparator","slug":"placebo-for-comparator","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"JTE-451 Tablets","genericName":"JTE-451 Tablets","slug":"jte-451-tablets","indication":"Inflammatory bowel disease","status":"phase_2"}]}],"pipeline":[{"name":"JTT-861 Capsules","genericName":"JTT-861 Capsules","slug":"jtt-861-capsules","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JTE-451 Tablets","genericName":"JTE-451 Tablets","slug":"jte-451-tablets","phase":"phase_2","mechanism":"JTE-451 is a selective antagonist of the P2X7 receptor, which modulates immune cell activation and inflammatory responses.","indications":["Inflammatory bowel disease","Rheumatoid arthritis"],"catalyst":""},{"name":"Placebo for comparator","genericName":"Placebo for comparator","slug":"placebo-for-comparator","phase":"phase_3","mechanism":"This drug has no known mechanism of action.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE54YTd6U0Z6bkhSVmR3cEFEd2lESjRaQjRpZU1paTR6T1dmQjVJTFJETkd3UXNSaGdja1NQbDFocDVaZHV0M0NyRThZT2REM1RWYldvMTJQanRiYS00NzEzVTB1Njl1bEpOQ19ST0x6cmUzTlRKZ2pOZDQtNnI?oc=5","date":"2026-03-31","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2026: Lipella, IO shutter; Takeda plots 634 US job cuts - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2026: Lipella, IO shutter; Takeda plots 634 US job cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOMUYzeS10MGg1WFJzTEJnUjdqeHQyRmEzZTRwZmpWMEtaVi1wYUZWU3lEd1JubWhhc3Z4ZzZJNDZ3ZXFfWU5acF9wX2QxN0RJZm13Y2JZRlh4cW1OUG80eUhLSnE5SmpRdUNTUlZ1WDM4cThRb0s1bm5TWXpzUGpjdkNRMXlxRjZVWk1NaEhLNUtWRWQ4czUzX1hRZWNYSVdmTkhkcndCdw?oc=5","date":"2025-12-23","type":"earnings","source":"BioWorld News","summary":"Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact - BioWorld News","headline":"Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPYWNMMHhMajJ5UkdBVEdfSkxQaFBQc25acFlwQy03cTB6V21vUEJkZDdiaGZHTHlyemxTUXNkRTNvNFZOZENXTmZoRzhCMlZfYzlfbGVOUDZ4QXgxQ18tYkVzRmNkV2ZpMjRYT3M1OFJmczh6dHl2QVY5YUxud3NxTzUtWk4wU2xJRHc?oc=5","date":"2025-11-25","type":"trial","source":"Yahoo Finance","summary":"Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight - Yahoo Finance","headline":"Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveIn","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOMEVRdlFpMUNnUFhzZ1ZiSGdJbWFrMll6QkhEOWNyTUNmdEV6MS05bmVVdjl6T2Z0dE9aM3ZOaHNPWmRTRm9Za1c2NlRYYmFzcXFrRU82MkpsTlBBcWZRbEU2SWRpZ2VtRjRfM3B6cFVqNDgzdGV3NzEtTlNLNzZSeTVsSzBxbWpXZF9qSDhnM0lURGRfYjJvYkloMzF0SXdi?oc=5","date":"2025-05-08","type":"deal","source":"BioWorld News","summary":"Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld News","headline":"Shionogi to acquire Japan Tobacco pharma companies for $1.1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOaW5hNkRSdHZidHhPd1pLVUNTdnhfQTh1NGJfNVoxa1NtUS1qcFhQSGJXM2xwU29oYWRyZmZYZkRaOGdQd2RWWUpXWmZ6bmFQT3FCYXM1bHRUQXdueXFCUDNZdVdEaFRRYVlhamdYMFRMMEhSbU9nSXp3cGR1SC1Xckp4dTF6UVoyX01jUUpvNjhkUlhPbFc2U045SDNfM0UzNmVUOEY5aXdsYnBtb2tjNWMtT2taUVlCczJnVFlGTGVmdw?oc=5","date":"2025-05-08","type":"pipeline","source":"The Pharma Letter","summary":"Shionogi pushes 2030 vision forward with $1 billion acquisition - The Pharma Letter","headline":"Shionogi pushes 2030 vision forward with $1 billion acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPU3RGMlFjcVVhSnVqOE1mbUlPNEtjOEU2V1hlNG05czhRZ3B1MkZRY0pTTHR5UEFqQTlJUnYyOUI1N0lodDl5N1V2S1NRQ0VmdkdVVTRHa1hpTmVPeTZ3eUVlV1lFREV1ZlFkMmpPZkZ5WWFCSDFQSU8wdER1ZXI2R25LWl80Q3ZGVm9OU24xd2I0VENzcVlUc0NlUHhZektWNldUR01ZNUdlYTNyNV9uLUJvUjc5dXBDMU1YTTlYeFNPVVFSRHRPLUgxQVRFZ2tSVWpTVlk1MGg4WTdDTzBnVXh0NV9ELW5sVFlBNG5IdzJsX0JvWkZoRkx6eThJRHRZQmUxMXZkYlFnMzZCX1p3X2x6U3hEUE90eERTZmwyV1Fhd2R2a2lMT184UVMzckdjNFVscENEMUFzbjdJaUgyUzBYcG5SRUk3V0w4dWhBTVhNWVU?oc=5","date":"2025-03-31","type":"regulatory","source":"Barchart.com","summary":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma Co. Ltd., Teijin Pharma -","headline":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOSERqOXo3RmVqLWUzVzZROGdjeDdMWUJFRDFndFFuUEVKZVB1ZUFyN0trS3Q2ZkJZVC1BamQtdTBHYzlacGRqVTZIMC1tX04zc1NXV21URmlNSHlPMjMwYkozMHdacFVsNnljVURabG43YWo0bGdOSUlaNmVpZGVYWk5zZzREUDVSNFNaVVBodnQtSEdBLWRBRUNUM2ZzUldVUl85cGw2S0daYk9oLUFUQXFqdWJmdGh0d1JkTzh3anZORm5wMk5oZU55ZE5PN2FWYnBiQThGUW9waE10amtuSXMyQkYzaTdvckl3dHVQUERITlJzVmxKMnpNSDB4M1lpZ212cWQ1T3JVR2l6YVo1U3lLS3I?oc=5","date":"2025-03-04","type":"regulatory","source":"PR Newswire","summary":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight - PR Newswire","headline":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZnFvSjFFMDhWWkpCYjNhUG44UTlRWGR5eXhSdnNTNEIxem1jSkV3WldMd1d0U3d4c1hYYm5kS29aQjY0R0h0enYzOHhFeW0wc3dQdUFScGo1U09hbUtYWnRBTE9DbHNBbUdzU2FXQXY0OE1sb0pCZldrb0tXamxGU2tmSjQ2OXIwNGY2TEtWQUExYW5UM0dxaTZjVERrME1wcmxPSTRCVkY5Zm0zWk5DeTNhY1hfaHU0Zy1J?oc=5","date":"2023-03-24","type":"trial","source":"Healio","summary":"Izokibep shows promise in early phase 2 hidradenitis suppurativa trial - Healio","headline":"Izokibep shows promise in early phase 2 hidradenitis suppurativa trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQTDFmdkpKeGFDMGEzYmtaUGVMclh2bFpuYS1NNFhucWt5NXl3STIzTF9kVTJDVEF2ZnNLSDlfb2phcmRDN1MzTzV3X01zS1RSVXU3ZHdZQTJvTkdiM1dVSGxndTB6akxPMkM0OEh1cUl5bjdCS2JpcUlBbkJLWm83djNzQmp2Mk9W?oc=5","date":"2022-12-09","type":"pipeline","source":"The SaaS News","summary":"Akros Technologies Raises $2.3 Million in Funding - The SaaS News","headline":"Akros Technologies Raises $2.3 Million in Funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPYXFwZ3BwV3JmVkVSakFUUnpaQVhFcFdseXlEY3RIUUdTMFVlaC1HR0RuQkhYSDYzQW1UcGU3R2pHOGZOUHhKUjdtQ3FPQzcwY1VVLWJPOUFjZUdkS3FVSExlRUJmdlNaZHJTNDB1bktlMHVwQ04xdnoxQTI5WWg2MnJ1UmZ5NGUxMnVqbS13dzdKdUZ5RlZNS2xoWVVRWmpPRTBpbUZLMF9SVVFXYWRJeXlZYkRqd2NBXzV0OE9wU1p4YXM1enVtbl9zRElqQjhpX0swUldGcy0xTlRXbU5lbG9HeXhreEg3elllYW1Hc2RSY3pTU3ZWWEVIYWE1NV90Uld3X05vbXQ?oc=5","date":"2022-07-26","type":"pipeline","source":"PR Newswire","summary":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight - PR Newswire","headline":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFB1MWp3U1FqT21CUFVoaVM4OC1iUU1JUUtPeXptSjV3WlVDa3JwMHpQb1B3RG9LZWc3UUJTNktZSnI2YjE2VjFaYlk3WEhVUEtianMwUldoa2RwS3JzVDBYdHZUZXFjVlkyc3c?oc=5","date":"2018-02-13","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNZVZrUFo5eU1QWFJMaXl6b0lyeHR5U1VEdHdhSkNmbmJZdFRLdC1PWTRTdWRoVmEtV3oyOF9ZM3dKbFVBdHpmZUJEMHBQNU1YU1dJOE9QMkFzOVppVG4tZE1jY3NsX203VXFmbGtZMUFwbzJFelhmYmJ6bXZUNldZTDhJbDVQNzZMbXlNNDMwMDRveTZUQWd4QTdVbGhyd2FWUjdNVXR6ZUczX0ZObHlvRFBYSHRYLWVUd1BNdE1nLTh6ZjJiazZDQ1Jn?oc=5","date":"2017-05-16","type":"pipeline","source":"European Medical Journal","summary":"Changing the Game in Ulcerative Colitis: The Impact of Gut-Selective Therapy - European Medical Journal","headline":"Changing the Game in Ulcerative Colitis: The Impact of Gut-Selective Therapy","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}